MC13-0086 Acquired resistance to Hedgehog inhibitor through smoothened mutation in basal cell carcinoma

Abstract

5-years DFS rates for de discovery set were LS=89%; IS=64.3%; HS=48.4% (P=0.001) and for the validation set were LS=89.8%, IS=77.2%; HS=67.9% (P=0.007). In the validation set, patients with residual disease had 5-years DFS rates of LS=85.4%, IS=73.7%; HS=58.7% (P=0.004). Differences were also observed in the groups with clinical stages I/II (P=0.031) and clinical stages III (P=0.005), but not for PAM50 subtypes. Conclusions: Levels of expression of genes involved in TLR4 signal transduction plays an important role in response for Taxanes-Anthracyclines therapy. We were able to identify a subgroup of patients with low score of signalling genes who could benefit from taxane-based therapies.